First social-health research on the use of seawater in respiratory diseases
7 out of 10 users preferred seawater to traditional serum, claiming it even reduces sick days.
Reig Jofre has collaborated in the first worldwide social-health research on the use of seawater for hygiene and relief of symptoms in upper respiratory tract disease.
This research has been promoted by the Spanish Society of Outpatient Pediatrics and Primary Care (SEPEAP), supported by the Spanish Society of Allergology and Clinical Immunology (SEAIC) and the Spanish Society of Otorhinolaryngology (SEORL). Participating were 175 physicians specialized in the treatment of upper respiratory tract diseases in the areas of pediatrics (50%), otolaryngology (30%) and allergology (20%), and 1350 users of seawater of all ages.
Delphi methodology was used in the study among specialty physicians. The results were presented at the SEPEAP conference, held earlier this month Santander (Spain).
According to Venancio Martinez Suarez, Chairman of SEPEAP said: “it is a pioneering program worldwide, in which the main scientific societies involved in nasal health and in the recommendation of seawater as adjuvant treatment have participated to establish both the basis of consensus and discussion on the different seawaters and the beginning of training and information initiatives for health professionals and users on practical recommendations on the use of seawater in hygiene and respiratory diseases, and for improving the level of knowledge of the different seawaters.
Of the specialists who participated in the research, 8 out of 10 agreed on the convenience of using seawater versus physiological serum for congestion, rhinitis, sinusitis, allergic rhinitis or nasal hygiene. Seven out of ten users said they preferred seawater to traditional serum, as it is easy to use, produces a pleasant sensation, and reduces sick days.”
The first decalogue worldwide for recommendations on nasal washing with seawater has been elaborated as a result of this research, based on the characteristics of the different seawaters, their beneficial effects, and their indications as a relief treatment for symptoms such as nasal congestion and mucus.
This decalogue of recommendations establishes that it is generally preferable
In addition, a national survey was carried out among the users of seawater in the nasal lavage to determine the perception of benefits, habits of use and global satisfaction.
More than 1300 users participated in the survey, most of whom reported having used the product Sterimar marketed by Reig Jofre. Among the main benefits observed regarding physiological serums were
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance